Review Article

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis

Table 2

Meta-analysis of the prevalence of HBV reactivation among patients treated with biologic agents.
(a)

First author, yearNumber of patientsHBV reactivation ( )HBV reactivation (%)CI 95%Weight (%)

All  patients
Caporali et al., 2010 [11]6700.00.0–5.410.9
Cassano et al., 2011 [12]6200.00.0–5.810.7
Charpin et al., 2009 [13]2100.00.0–15.57.5
Kim et al., 2010 [14]881415.99.7–24.911.4
Lan et al., 2011 [15]8866.83.2–14.111.4
Mori, 2011 [16]3213.10.6–16.28.9
Ryu et al., 2012 [17]4936.12.1–16.510.1
Tamori et al., 2011 [18]4400.00.0–7.19.8
Urata et al., 2011 [19]5259.64.2–20.610.3
Vassilopoulos et al., 2010 [20]3313.00.5–15.39.0
Pooled estimate4.21.48.2100.0

Heterogeneity chi-squared = 35.55 (d.f. = 9) = 0.000.
-squared (variation in ES attributable to heterogeneity) = 74.7%.
(b)

First author, yearNumber of patientsHBV reactivation ( )HBV reactivation (%)CI 95%Weight (%)

Patients  with  overt  chronic  HBV  infection
Lan et al., 2011 [15]18527.812.5–50.945.5
Ryu et al., 2012 [17]4936.12.1–16.554.5
Pooled estimate15.41.2–41.2100.0

Heterogeneity chi-squared = 4.98 (d.f. = 1) = 0.026.
-squared (variation in ES attributable to heterogeneity) = 79.9%.
(c)

First author, yearNumber of patientsHBV reactivation ( )HBV reactivation (%)CI 95%Weight (%)

Patients  with  occult  HBV  infection
Caporali et al., 2010 [11]6700.00.0–5.412.3
Cassano et al., 2011 [12]6200.00.0–5.812.1
Charpin et al., 2009 [13]2100.00.0–15.58.9
Kim et al., 2010 [14]881415.99.7–24.912.8
Lan et al., 2011 [15]7011.40.2–7.712.4
Mori, 2011 [16]3113.20.6–16.210.2
Tamori et al., 2011 [18]4200.00.0–8.411.3
Urata et al., 2011 [19]5259.65.4–23.011.7
Vassilopoulos et al., 2010 [20]1900.00.0–16.88.6
Pooled estimate3.00.67.2100.0

Heterogeneity chi-squared = 34.94 (d.f. = 8) = 0.000.
-squared (variation in ES attributable to heterogeneity) = 77.1%.